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pressure and low salt status (2) . However, in primary aldosteronism (PA), overproduction of aldosterone, caused by adenoma or hyperplasia of one or both adrenal glands, is relatively autonomous of the RAS, levels of which are usually suppressed (3) . Such inappropriate aldosterone production in PA leads to (1) excessive sodium retention, which causes volume expansion and hypertension; (2) increased potassium excretion which, if severe and prolonged enough, may lead to hypokalemia (4); and (3) adverse cardiovascular and renal consequences (5, 6) .
PA is now recognized as the most common endocrine cause of hypertension with a prevalence approaching 5% to 13% (7) (8) (9) . Early diagnosis of PA is of considerable potential benefit to affected individuals, because unilateral adrenalectomy (ADX) results in cure or improvement of hypertension in patients with unilateral PA, whereas specific drugs (such as mineralocorticoid receptor antagonists) that antagonize aldosterone action usually have substantial beneficial effects on control of hypertension in bilateral PA (10) . The diagnostic workup of PA includes: (1) screening for PA by aldosterone/renin ratio (ARR) testing, (2) confirmatory testing [e.g., by fludrocortisone suppression testing (FST) or saline infusion testing (SIT)], and (3) determining the PA subtype, primarily involving distinguishing unilateral from bilateral PA by adrenal CT and adrenal venous sampling (AVS) (11) . Accurate measurement of peripheral (plasma or serum) aldosterone concentration (PAC) is essential for all stages of PA diagnostic workup, with ARR reliant on accurate assays of both aldosterone and renin [direct renin concentration (DRC) or plasma renin activity (PRA)], FST dependent on precise quantification of aldosterone (as well as renin and cortisol), and AVS reliant on reliable assays of aldosterone and cortisol.
Because peripheral aldosterone circulates at picomolar concentrations, accurate measurement of PAC requires highly sensitive and specific assays. Currently, PAC is most often measured by antibody-based immunoassays (12) that have demonstrated lack of high specificity (causing overestimation of PAC) (13) and variability in assay performance among different laboratories. Therefore, in the past decade, there has been growing interest in quantifying PAC by using liquid chromatography-tandem mass spectrometry (LC-MS/MS), which has been reported to be more reliable than traditional radioimmunoassay (RIA) (14) . However, studies evaluating this emerging approach with regard to assay-specific cutoffs for PA screening and confirmatory testing are rare (15) .
In 2009, our center reported on the development of an aldosterone LC-MS/MS assay that was highly accurate and reproducible (16, 17) . Subsequent analysis within our laboratory has revealed a lower value of PAC measured by this approach (PAC LC-MS/MS ) compared with RIA (PAC RIA ), probably at least in part because of the improved specificity of LC-MS/MS. These results suggest that when undertaking screening and confirmatory testing for PA, reduction in current threshold values for the ARR and FST (which were both established using PAC RIA ) would be necessary if PAC is measured by LC-MS/MS.
In the current study, we applied regression equations derived from our comparison results of two aldosterone assays as well as consideration of clinical factors to calculate PAC LC-MS/MS -specific threshold values for the ARR and FST, and then evaluated the performance of these threshold values by measuring both PAC LC-MS/MS and PAC RIA in patients who had undergone FST in our center.
Subjects and Methods

Study design and participants
This study was approved by the Human Research Ethics Committees of the Princess Alexandra Hospital, the Greenslopes Private Hospital, and the University of Queensland (HREC/13/QPAH/229). Forty-one patients (19 males and 22 females; age range, 37 to 73 years) were recruited according to the following inclusion criteria: patients who were hypertensive with positive ARR screening results (PAC RIA /DRC .70 pmol/ mU) who were undergoing FST to definitely confirm or exclude PA as the cause of their hypertension (n = 33) and patients with previously confirmed unilateral PA who had undergone unilateral ADX (n = 8) and were completing postsurgical FST to determine whether PA had been biochemically (or clinically) cured (Supplemental Table 1 ) or residual disease was still present. For each FST study, four samples were collected (at 7:00 AM after overnight recumbency and 10:00 AM after 3 hours' upright posture on both the basal day and on day 4 of FST). Patients with severe, uncontrolled hypertension, heart failure, or impaired liver or renal function were excluded because of concerns about the risk of fluid overload associated with oral salt loading during FST. To permit meaningful analysis of the diagnostic performance of ARR and FST PAC cutoff values, only FST studies that yielded conclusive results (PA positive or PA negative) were included in this study. A detailed description of the FST procedure and definitions of positive and negative FST results are provided in Online Supplemental Data. Clinical characteristics of the study population are displayed in Table 1 .
Routine clinical measurement of plasma PAC and DRC
Plasma PAC RIA and DRC were measured routinely during FST in the laboratory of Pathology Queensland (PQ, Brisbane, Australia). PAC RIA was determined by the Coat-a-Count TM aldosterone RIA kit (Diagnostic Products Corp.). The interassay coefficient of variations (CVs) was 11% at 164, 6% at 690, and 7.1% at 1409 pmol/L. The intra-assay CVs were 6.8% at 171, 4.9% at 705, and 5.9% at 1467 pmol/L. DRC was determined by the LIAISON® XL immunoanalyzer (DiaSorin, Italy) using a chemiluminescent immunoassay (CLIA) kit (DiaSorin, LIAISON® Direct Renin, Italy). The interassay CVs were 7.4% at 27 mU/L and 6.0% at 107 mU/L. The intra-assay CVs were 3.7% at 15, 2.0% at 82, and 1.2% at 258 mU/L. The functional sensitivities for the PAC RIA and DRC assays reported by the manufacturer were 30 pmol/L and 2 mU/L, respectively. Among the total of 164 EDTA plasma samples collected from the 41 patients during FST (4 samples per FST), none was found to have PAC RIA ,30 pmol/L, whereas 76 (46.3%) samples were reported with DRC ,2 mU/L.
LC-MS/MS-based quantification of serum PAC
For this evaluation study, gel-free serum was collected prospectively during FST and was stored at 220°C immediately after collection. All 164 FST serum samples underwent measurement of PAC LC-MS/MS in the laboratory of Attoquant Diagnostics (AD, Vienna, Austria). When ready for assay, samples (200 mL) were spiked with stable isotope-labeled internal standard for aldosterone at a concentration of 1387 pmol/L (500 pg/mL). Following C18-based solid-phase extraction and fractionated elution of aldosterone, samples were subjected to LC-MS/MS analysis using a reversed-phase analytical column (Acquity UPLC® C18, Waters) operating in line with a XEVO TQ-S triple quadrupole mass spectrometer (Waters Xevo TQ/S, Milford, MA) in multiple reaction monitoring mode. The internal standard was used to correct for analyte recovery across the sample preparation procedure in each sample. Analyte concentrations were calculated from integrated chromatograms considering the corresponding response factors determined in appropriate calibration curves in serum matrix, on condition that integrated signals exceeded a signal-to-noise ratio of 10. The functional sensitivity for PAC LC-MS/MS assay was 14 pmol/L, and there were only two (1.2%) serum samples from one postsurgical patient that were reported with PAC LC-MS/MS ,14 pmol/L. At 50 pmol/L serum, the interassay and intraassay CVs for PAC were 7.9% and 5.2%, respectively.
Choices of aldosterone assay-specific cutoffs for the ARR and FST used in this study To establish a diagnostic cutoff for FST PAC LC-MS/MS , we first confirmed that the adjusted cutoff should be lower than that for PAC RIA by deriving a regression equation for PAC. For the purpose of the current study, our previous assay comparison of PAC LC-MS/MS between the two laboratories (PQ's plasma PAC LC-MS/MS vs AD's serum PAC LC-MS/MS ) was undertaken using 124 pairs of plasma and serum samples and demonstrated excellent agreement (Supplemental Figure 1) , in particular within a PAC range between 0 and 600 pmol/L, within which no potential outliers were present. Hence, in this study, an extended comparison between aldosterone LC-MS/MS and RIA results was carried out by combining the data derived from our previous in-house PQ's analysis (plasma PAC RIA vs plasma PAC LC-MS/MS , n = 311) described above for ARR and the current 164 pairs of FST samples in which plasma PAC RIA was measured by PQ and serum PAC LC-MS/MS was analyzed by AD, giving a total of 475 results available for comparative analysis (Fig. 1 ). This yielded a regression equation of PAC LC-MS/MS = 0.82 3 PAC RIA -24.4 (r 2 = 0.85). We then assessed the performance characteristics of a range of cutoffs approximating that predicted by this regression equation (for PAC RIA = 165 pmol/L, PAC LC-MS/MS = 111 pmol/L) among a larger FST database to ensure that the final selected cutoff was most relevant clinically. In particular, we sought to determine a cutoff that (1) would minimize the rate of false positives in patients who had clearly been cured of PA by unilateral ADX using the criteria established by the Primary Aldosteronism Surgical Outcomes study (19) , and (2) minimize the rate of false negatives in patients with unequivocal unilateral PA, defined by lateralization on AVS. The reasoning for this approach was based on the notions that (1) the primary purpose for confirmatory testing is to identify among patients with raised ARR those who do not have PA and who therefore can be spared AVS, an invasive and costly procedure not without risk; (2) the main role of AVS is to identify those subjects with unilateral PA who are potentially curable by, and therefore candidates for, unilateral ADX; and therefore that (3) confirmatory testing should ideally accurately identify patients who do not have PA, but not miss those with unilateral, surgically correctable PA. Applying these clinical considerations, we found that a cutoff of 133 pmol/L correctly ruled out PA in all patients cured of PA by unilateral ADX and correctly identified PA in all patients who lateralized on AVS. We therefore chose 133 pmol/L as the FST PAC LC-MS/MS cutoff in this study. was used to analyze the data. Nonnormally distributed data are presented as median and interquartile range. Spearman nonparametric correlation and simple linear regression analysis were used to assess the relationship between PAC RIA and PAC LC-MS/MS . Bland-Altman analysis was used to evaluate the bias and agreement between two aldosterone assays by using GraphPad Prism 7 (GraphPad Software, La Jolla, CA). Independent samples Mann-Whitney U test was used to compare the data between the FST-negative and FST-positive groups.
Statistical analysis
McNemar test was used to compare the difference in sensitivity and specificity of different threshold values. P , 0.05 was considered statistically significant. For statistical analysis, DRC and PAC LC-MS/MS below 2 mU/L and 14 pmol/L were rounded up to 2 mU/L and 14 pmol/L, respectively.
Results
Comparison of PAC RIA and PAC LC-MS/MS
Our previous in-house comparison between the two aldosterone assays (PQ, n = 311) revealed an ;28.0% higher estimation ( FST results (29 positive and 8 negative) by the two aldosterone assays, whereas four showed inconsistent results (Table 2) . A good agreement (k coefficient = 0.736, P , 0.01) and no difference (P . 0.05) in distinguishing positive and negative FSTs were observed between the two FST PAC RIA and PAC LC-MS/MS cutoffs. Further comparison between patients who were FST-negative (n = 8, including 7 post-ADX) and patients who were FST-positive (n = 29, none post-ADX) showed that, as expected, patients who were FST-positive (PA) had higher (P , 0.01) levels of PAC and ARR than patients who were FST-negative (non-PA or PA cured) on both days 0 and 4 of FST, but in this study, the differences of DRC between two groups were not significant (P . 0.05) on both days (Table 3) .
Performance of two ARR threshold values for screening PA
Among the 37 patients whose FST results were consistent, patients' ARR data at 10:00 AM on basal day (before FST) was used to examine the screening performance of two ARR threshold values. If using ARR RIA .70 pmol/mU and ARR LC-MS/MS .55 pmol/mU as cutoffs, four (10.8%) patients showed false screening results, including two patients with PA (FST positive) who displayed both false-negative ARR RIA and ARR LC-MS/MS , one patient who was non-PA (FST-negative, none post-ADX) who displayed both false-positive ARR RIA and ARR LC-MS/MS , and one patient with PA who demonstrated correct positive ARR LC-MS/MS but false-negative ARR RIA . False-negative rates for the two assay-specific ARR cutoffs were 10.3% (RIA) and 6.9% (LC-MS/MS), whereas false-positive rates for these two cutoffs were identical at 12.5%. The differences in sensitivity (89.7% for RIA vs 93.1% for LC-MS/MS) and specificity (87.5% for both assays) between the two assay-specific ARR cutoffs were not notable.
Discussion
Because ARR screening results can be falsely positive (20) (21) (22) (23) (24) (25) , confirmatory testing is necessary to definitively confirm or exclude the diagnosis of PA. Compared with other widely used confirmatory tests for PA, FST is regarded by our center to be the most sensitive and reliable (26) (27) (28) . The basis of FST as a confirmatory test for PA involves demonstration of ongoing aldosterone secretion in the face of suppression of renin achieved by fludrocortisone administration and oral salt loading. As mentioned earlier, a reliable aldosterone assay is important for judging whether FST is positive or negative for PA; this hinges mostly on day 4 PAC levels. At present, PAC is most often measured by RIA (29) but can also be assayed by a faster and automated CLIA method (30, 31) . However, concerns have been raised about the weaknesses of these immunometric techniques. First, the specificity of antibodies for RIA and CLIA varies between assays, which is likely from interfering substances in tested samples such as structurally related steroids (as well as their precursors and metabolites) that have the potential for cross-reactivity with the aldosterone assay antibody (13) , thereby causing overestimation of PAC, which is especially problematic because the PAC is relatively low compared with many potentially interfering steroids. Second, inadequate standardization of assay procedures in different laboratories, poor interlaboratory reproducibility, and limited comparability of immunoassays remain problematic and impose barriers in defining a uniform cutoff for PA diagnostic workup (32). Schirpenbach et al. (33) compared four aldosterone immunoassays (in-house RIA after extraction and chromatography vs two commercial RIA kits without extraction vs automated CLIA) and reported that they gave markedly different results.
A major recent advance in aldosterone quantification has been the development of a highly accurate and reproducible mass spectrometric or LC-MS/MS method, which has been proven to be highly reliable within the clinically relevant range (34) . The main advantages of the LC-MS/MS assay are high specificity and relatively rapid throughput (35, 36) while allowing for internal standardization by using stable isotopes, thereby normalizing for specific matrix effects and variations in analyte recovery during sample preparation, which are both features neglected by immunoassays. Unlike immunoassay, LC-MS/MS does not require a specific antibody to target the analyte and permits differentiation and measurement of aldosterone and other steroids together with their corresponding internal standards simultaneously in a single run from one sample, thereby providing more accurate and powerful clinical information (37) . It could be anticipated that, for aldosterone testing, the gold method should be based on LC-MS/MS detection (38) . However, the accessibility to LC-MS/MS equipment remains an obstacle to many clinical laboratories, and using LC-MS/MS also requires specific technical experience. In the current study, our previous in-house aldosterone assay comparison (PQ, plasma PAC RIA vs plasma PAC LC-MS/MS , n = 311) and current extended comparison during FST (PQ's plasma PAC RIA vs AD's serum PAC LC-MS/MS , n = 164 pairs) both revealed a lower (P , 0.01) value of PAC LC-MS/MS than PAC RIA (28.0% and 27.8% differences in the median, respectively), and yielded a total regression equation How did we select the aldosterone LC-MS/MS assayspecific threshold values for PA screening (ARR) and confirmatory (FST) testing in this study? The proposed ARR LC-MS/MS cutoff value of 55 pmol/mU was deduced by applying above ARR regression equation (in which the current ARR RIA cutoff value of 70 pmol/mU was used), derived from a direct comparison of ARR RIA and ARR LC-MS/MS performed in-house (PQ, n = 311) when we established this aldosterone LC-MS/MS assay for routine use in our hospital. This ARR LC-MS/MS cutoff proved to be highly sensitive (93.1%), a major prerequisite of a screening test, and with reasonable specificity (87.5%). When determining the FST PAC LC-MS/MS threshold value, we were mindful that both sensitivity and specificity (more so than screening) are important considerations for confirmatory testing in PA, given the undesirable consequences of overdiagnosing PA (which may lead to patients needlessly undergoing AVS, which is costly, difficult and invasive) and missing unilateral PA (which is potentially curable by unilateral ADX). Additionally, given that many factors (e.g., outliers, normality of data distribution) could affect the PAC equation and 95% confidence interval existed for the equation's slope (0.79 to 0.86) and intercept (243.4 to 25.4), we therefore assessed a range of cutoffs and settled on one (133 pmol/L) that was slightly higher than that predicted directly by our PAC regression equation (111 pmol/L, at which two patients, including one patient who was post-ADX, with negative FST results by RIA would be misdiagnosed as having PA), but that differentiated without overlap patients with unequivocal unilateral PA from those who were unequivocally cured of PA by unilateral ADX.
In this study, a good agreement (k coefficient = 0.736, P , 0.01) between PAC cutoff values of 165 (by RIA) and 133 (by LC-MS/MS) was observed in distinguishing FST-positive and FST-negative cases, with 37 patients showing consistent FST results. Importantly, among the remaining four patients with inconsistent FST results (Table 2 ) by the two aldosterone assays, one with normal potassium, unsuppressed renin, both negative ARR RIA and ARR LC-MS/MS , and negative SIT result showed positive FST by RIA but negative FST by LC-MS/MS; one with hypokalemia, suppressed renin, and both positive ARR RIA and ARR LC-MS/MS before FST demonstrated Although the ARR has been recommended by guidelines (11) as the most reliable approach for PA screening, its cutoff is not standardized among different laboratories and clinical centers, mainly because of lack of uniformity in assay methods and in the units used for reporting aldosterone (ng/dL or pmol/L for PAC) and renin (ng/mL/h or pmol/L/min for PRA; ng/L or mU/L for DRC). It is likely that this variability will diminish with time as more laboratories change from PRA to DRC and adopt the Systeme Internationale method of reporting PAC and DRC. Hopefully, the use of LC-MS/MS will further facilitate the standardization of aldosterone assay approaches and measured values. Indeed, in the current study, a comparison of PAC LC-MS/MS values measured by two different laboratories (PQ, AD) showed excellent agreement with an acceptable bias of 4.7% (or 1.0% if focusing on a PAC range between 0 and 600 pmol/L) (Supplemental Figure 1) . Currently, only a few studies have reported data on determining ARR screening cutoff by using PAC LC-MS/MS . Juutilainen et al. (15) recommended a cutoff value of 44 pmol/ng (sensitivity = 100%, specificity = 84%) derived from receiver operating characteristic (ROC) curve analysis, which equates to 27.7 pmol/mU and is therefore much lower than our figure of 55 pmol/ mU. However, antihypertensive medications, which are reported to affect the ARR, were used by .70% of the patients in Juutilainen's study. In our study, the estimates of sensitivity and specificity for the ARR RIA cutoff value of 70 pmol/mU (89.7%, 87.5%) and the ARR LC-MS/MS cutoff value of 55 pmol/mU (93.1%, 87.5%) were similar (P . 0.05), indicating the potential usefulness of this proposed cutoff value of 55 if PAC LC-MS/MS is measured.
Strengths of this study are that (1) PA diagnosis was confirmed by using FST; (2) potentially interfering factors (including antihypertensive medications, salt intake, hypokalemia, and time of day for sampling) to renin and aldosterone levels were all controlled and standardized before and during testing, which therefore improved the accuracy of the day 0 ARR results for PA screening; and (3) that this study attempted to validate an aldosterone LC-MS/MS assay-specific cutoff for FST. However, this study is not without limitations. No healthy (normotensive) subjects (other than those cured of hypertension post-ADX) and no patients who were hypertensive with consistently negative ARR were included in this study because FST requires 5 days of hospitalization, rendering it unfeasible to undertake in patients for whom the test is not clinically indicated. Among the 41 total participants, 10 (including all 8 patients who were post-ADX and 2 patients who were FST-positive) showed negative ARR screening results on day 0 by the two aldosterone assays, and one patient who was FST-positive showed negative ARR RIA but positive ARR LC-MS/MS results. Because of the relatively low number of patients with raised ARR who ended up with negative FST results, we elected to include patients who were post-ADX as a means of expanding the FST-negative cohort. In the current study, of eight patients who were FST-negative (confirmed by the two assays), seven had been previously diagnosed with unilateral PA and had undergone unilateral ADX, leading to the complete biochemical (or clinical) cure of PA (Supplemental Table 1 ). This probably explains why there was no difference in DRC on day 0 between the FSTpositive and FST-negative groups because the RAS activity of these patients who were post-ADX may not have fully recovered from its chronically suppressed state. The difference in sample matrix may also raise concerns. In this study, EDTA plasma was used for measuring PAC RIA , whereas serum was used to measure PAC LC-MS/MS ; however, Taylor et al. (16) and Van Der Gugten et al. (39) reported that the aldosterone assay results were not affected significantly by these specimen types. Finally, although we previously calculated an optimal ARR LC-MS/MS screening cutoff value of 52.4 pmol/mU using ROC curve analysis (40) , the currently proposed ARR LC-MS/MS and FST PAC LC-MS/MS cutoffs were derived from the comparison results between PAC RIA and PAC LC-MS/MS rather than from ROC curve analysis. Therefore, further studies involving larger populations and healthy controls and patients with essential hypertension are required to further validate our recommended LC-MS/MS cutoffs. Furthermore, because this analysis was limited to FST, additional studies are necessary to establish and validate cutoff PAC LC-MS/MS values for other commonly used confirmatory tests (including SIT).
Conclusions
In summary, our results provide preliminary evidence supporting the satisfactory performance of proposed cutoffs for PA diagnostic workup specific for PAC measurement by LC-MS/MS. There was no difference in sensitivity or specificity between the current ARR RIA cutoff value of 70 pmol/mU and the proposed ARR LC-MS/MS cutoff value of 55 pmol/mU in PA screening or between the current FST day 4 PAC RIA cutoff value of 165 pmol/L and proposed PAC LC-MS/MS cutoff value of 133 pmol/L in PA definitive testing by FST. These data emphasize the need for adjustment of current threshold values for PA screening and confirmatory testing if aldosterone is measured by LC-MS/MS.
